Compare Organon & Co. Common Stock (OGN) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tempus AI — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tempus AI trades at $67.08 (market cap $12.39B). The key difference: Tempus AI is far larger — about 3.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tempus AI for 23 Days on average.
| OGN | TEM | |
|---|---|---|
Market Cap | $3.62B | $12.39B |
Volume | 2,892,999 | 4,141,569 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $92.45 |
52-Week Low | $5.70 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.04B | $13.01B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
